Clinical, microbiological, and molecular characteristics, outcomes, and risk factors for mortality of patients with Stenotrophomonas maltophilia bloodstream infection
Authors:
- Gawahir A. AliGAGawahir A. Ali
- Maha Y. Al-JabriMAMaha Y. Al-Jabri
- Wael GoraveyWGWael Goravey
- Khaled M. ShunnarKSKhaled M. Shunnar
- Mostafa NajimMNMostafa Najim
- Joanne DaghfalJDJoanne Daghfal
- Jemal M. HamidJHJemal M. Hamid
- Ahmed M. HassanAHAhmed M. Hassan
- Emad B. IbrahimEIEmad B. Ibrahim
- Faiha EltayebFEFaiha Eltayeb
- Ali A. SultanASAli A. Sultan
- Hamad Abdel HadiHHHamad Abdel Hadi
Open Access
- 18 August 2026
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- p. 1-12
Abstract
Purpose: The aim of this study was to explore the clinical, microbiological, and molecular characteristics of Stenotrophomonas maltophilia bacteraemia, outcomes, and risk factors associated with mortality. Methods: This was a nationwide retrospective cohort study of patients with S. maltophilia bacteraemia during the period between January 2017 and December 2021. MIC Test Strips (Liofilchem, Roseto degli Abruzzi, Italy) were used for susceptibility testing, and Illumina for whole genome sequencing. Kaplan–Meier survival analysis and a multivariable Cox regression model were utilized to assess independent predictors of 90-day all-cause mortality. Results: Ninety patients were included, with a median age of 51.5 years (IQR 37–61), and 25.6% were females. The most common underlying medical conditions included diabetes mellitus (42.2%), and haematological malignancy (23.3%); and 64.4% were immunosuppressed. The most common sources of bacteraemia were the respiratory tract (38.9%) and vascular lines (25.6%). In vitro susceptibility rates were highest for trimethoprim-sulfamethoxazole (98.9%), and levofloxacin (61.1%). Sequencing demonstrated extensive genomic heterogeneity, and sul1 gene was detected in only one strain. The most frequent therapy was trimethoprim-sulfamethoxazole, monotherapy (77.8%) or in combinations (6.7%), for a median duration of 10 days (IQR 5–14). All-cause 90-day mortality was 44.4%. Receiving trimethoprim-sulfamethoxazole was associated with improved 90-day survival (log-rank P < 0.001), and was independently associated with lower mortality in the multivariable Cox model (hazard ratio 0.21, 95% confidence interval 0.06 to 0.74). Conclusion: S. maltophilia blood isolates are genomically diverse and remain mostly susceptible to trimethoprim-sulfamethoxazole. Using trimethoprim-sulfamethoxazole for patients with S. maltophilia bacteraemia appears to be associated with improved survival.Keywords
Funding Information
- Hamad Medical Corporation
This publication has 48 references indexed in Scilit:
- Rationale for contemporary antimicrobial treatment of Stenotrophomonas maltophilia: a narrative reviewCMI Communications, 2025
- Minocycline susceptibility in Stenotrophomonas maltophilia: a closer look at institutional data amid CLSI breakpoint revisionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2024
- Understanding the rationale and clinical impact of the revised CLSI 2024 minocycline susceptibility breakpoints against Stenotrophomonas maltophiliaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2024
- Trimethoprim-sulfamethoxazole versus levofloxacin for the treatment of Stenotrophomonas maltophilia infections: A multicentre cohort studyJournal of Global Antimicrobial Resistance, 2024
- In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004-2020International Journal of Antimicrobial Agents, 2023
- Versatility of Stenotrophomonas maltophilia: Ecological roles of RND efflux pumpsHeliyon, 2023
- Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapyInternational Journal of Antimicrobial Agents, 2021
- Clinical characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative bacteria from critically ill patients with COVID-19Journal of Hospital Infection, 2021
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialThe Lancet Infectious Diseases, 2021
- The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist Stenotrophomonas maltophiliaNature Communications, 2020